Abstract
Cervical cancer is an infectious cancer and the most common gynecologic cancer worldwide. E6/E7, the early genes of the high-risk mucosal human papillomavirus type, play key roles in the carcinogenic process of cervical cancer. However, little was known about its roles in modulating tumor microenvironment, particular extracellular matrix (ECM). In this study, we found that E6/E7 could regulate multiple ECM proteins, especially collagen triple helix repeat containing 1 (CTHRC1). CTHRC1 is highly expressed in cervical cancer tissue and serum and closely correlated with clinicopathological parameters. CTHRC1 promotes cervical cancer cell migration and invasion in vitro and metastasis in vivo. E6/E7 regulates the expression of CTHRC1 in cervical cancer by E6/E7-p53-POU2F1 (POU class 2 homeobox 1) axis. Futhermore, CTHRC1 activates Wnt/PCP signaling pathway. Take together, E6/E7-p53-POU2F1-CTHRC1 axis promotes cervical cancer cell invasion and metastasis and may act as a potential therapeutic target for interventions against cervical cancer invasion and metastasis.
Similar content being viewed by others
Introduction
Cervical cancer is an infectious cancer and the most common gynecologic cancer worldwide. Repeated and persistent high risk HPV infection is found to be a major cause of cervical cancer and cervical intraepithelial neoplasia (CIN) III1,2. Extensive studies indicate that the products of the early genes, E6 and E7, of the high-risk mucosal HPV types play a key role in the carcinogenic process of cervical cancer3. The viral E6 and E7 oncoproteins inactivate the p53 and pRb proteins and abolish their cancer prevention effects, respectively. However, only minority persistent HPV infection transforms into cervical cancer, so only HPV infection is not enough for malignant transformation of cervical cancer. Additional pathogenic factors, like microenvironment, must be required for cervical cancer development.
Evidence has been accumulated over the past 10 years that the microenvironment in which cancer arises plays a critical role in tumorigenesis4,5. Tumor microenvironment is a complex integrated system, which play important roles in tumor proliferation, invasion, metastasis, angiogenesis and immune response. The growth and metastasis of tumor depend not only on the cancer cell itself, but also on the interaction between cancer cells and their microenvironment. Extracellular matrix protein is one of the main components of the tumor microenvironment. Induced by either tumour cells or tumour stromal components, matricellular proteins initiate downstream signalling events that lead to proliferation, invasion, matrix remodelling and dissemination to pre-metastatic niches in other organs6. However, little research has been performed on how HPV E6/E7 affects microenvironment, particular extracellular matrix proteins and their receptors, and finally leads to the occurrence and metastasis of cervical cancer.
In this study, by silencing of E6/E7 in high-risk HPV16 or HPV18 infected cervical cancer, we identified multiple microenvironment genes which were altered after E6/E7 silencing. Among them, CTHRC1 is of particular interest to us. Our results showed that CTHRC1 promotes cervical cancer cell migration and invasion in vitro and metastasis in vivo. We also demonstrated the molecular mechanism of how E6/E7 regulates the expression of CTHRC1, which provides a new evidence for E6/E7 promoting cervical cancer metastasis by modulating microenvironmental factors.
Results
Extracellular matrix expression profile is altered by silencing of E6/E7
Since E6/E7 play a key role in the carcinogenic process of cervical cancer, we performed a whole-genome microarray analysis by silencing of E6/E7 in Caski and Ms751 cells (Supplementary Figure 1). The results showed that 116 genes were down-regulated and 122 genes were up-regulated in Caski cells, 90 genes were down-regulated and 100 genes were up-regulated in Ms751 cells (fold change >3, P < 0.05) (Supplementary Figure 2). Twenty-one extracellular matrix genes including CTHRC1, GTF2I, INSL6, BIRC3, PTN, CLPX, IDE, HNRPDL, MFAP3, LRP8, POU2F1, TWSG1, NRXN3, GPD2, EXTL2, USP25, SLAMF7, ANGPTL4, KRTAP2-4, SYNPO and NCR3 were down-regulated in both cells (Fig. 1A and B). Among them CTHRC1 is of particular interest to us. The qPCR result confirmed that the expression of CTHRC1 was greatly reduced in Caski cells and Ms751 cells after silencing of E6/E7 (Fig. 1C and D).
CTHRC1 is highly expressed in cervical cancer and closely correlated with clinicopathological parameters
To further explore the clinical significance of CTHRC1, we firstly analyzed the expression of CTHRC1 in cervical cancer using The Cancer Genome Atlas (TCGA), Gene Expression Omnibus (GEO) dataset and Oncomine (http://www.oncomine.org). The expression of CTHRC1 in 303 cervical cancer tissues was significantly higher than those in normal cervical tissues in TCGA (Fig. 2A). In another TCGA dataset, the expression of CTHRC1 also increased in 3 cervical tumor tissues compared to the matched non-tumor tissues (Fig. 2B). In a dataset from GEO (GSE31056), the expression of CTHRC1 in 22 cervical cancer tissues increased compared to 12 normal tissues (Fig. 2C). Moreover, the expression of CTHRC1 in 20 cervical cancer was higher than those in cervix uteri (n = 8), oral cavity (n = 9), palate (n = 1) and tonsil (n = 4) in Oncomine dataset (Fig. 2D). Higher copy number of CTHRC1 was especially found in 13 non-keratinizing squamous cell carcinoma as compared with normal (n = 98), adeno-carcinoma (n = 1), keratinizing squamous cell carcinoma (n = 5) and squamous cell carcinoma (n = 83) in TCGA cervix (Fig. 2E). Further, we performed an immunohistochemical analysis of CTHRC1 in a tissue microarray containing 101 cervical squamous cell carcinoma tissue samples, 29 cervical adenocarcinoma tissue samples, 19 cervical intraepithelial neoplasia (CIN) and 30 normal cervical tissues. 130 cervical cancer tissue samples were obtained from patients infected with HPV16/18. Stronger CTHRC1 staining was detected in the cervical squamous cell carcinoma tissues and cervical adenocarcinoma tissues than that in CIN and normal cervical tissues (Fig. 3A and B). To further investigate the clinical significance of CTHRC1 expression in cervical cancer, we examined the correlation between the CTHRC1 expression status and clinicopathological characteristics of 101 cervical squamous cell carcinoma patients who were divided into two groups: the high expression group (n = 51) and the low expression group (n = 50). The results indicated that the expression level of CTHRC1 was closely associated with clinical stages (P = 0.0021), pathology grade (P = 0.0186) (Fig. 3C and D), lymph metastasis (P = 0.0075) (Fig. 3E and F), Lymphatic vascular invasion (P = 0.001), deep of invasion (P = 0.0001) and diameter of tumor (P < 0.0001) (Table 1).
CTHRC1 has no effect on cervical cancer cell proliferation in vitro and tumor growth in vivo
To explore the biological functions of CTHRC1 in cervical cancer progression, the expression of CTHRC1 in cervical cancer cells was detected by qPCR and western blotting (Fig. 4A,B and Supplementary Figure 6Aand B). CTHRC1 highly expressed cells Caski and Ms751 were transfected with shRNA-CTHRC1-(1, 2), designated as sh1 and sh2, or a mock vector, which was labeled as Nc. The silencing effects of the Lenti-shRNAs in these two cells were validated by qPCR and western blotting (Supplementary Figures 3A,B and 6C,D). Meanwhile, we established CTHRC1-overexpressing stable cells, which were transfected with a lentivirus carrying the CTHRC1 gene and labeled as Lenti-CTHRC1, using CTHRC1 lowly expressed cell lines Siha and Hela. Control cells were transfected with a mock vector and designated as Lenti-Crtl. CTHRC1 overexpression in these two cervical cancer cells was confirmed by qPCR and western blotting (Supplementary Figures 3C,D and 6E,F).
We first examined the effect of CTHRC1 overexpression/silencing on cervical cancer cell growth. The results showed that the overexpression/silencing of CTHRC1 has no effect on the proliferation of the cervical cancer cells in vitro by Cell Counting Kit-8 (CCK8) assay (Fig. 4C–F). To further confirm the results in vivo, Lenti-Crtl or Lenti-CTHRC1 cells (Siha) were subcutaneously inoculated into nude mice. The tumors derived from the Lenti-CTHRC1 cells had no difference with those derived from the Lenti- Crtl cells (Fig. 4G). The average volume and weight of Lenti-Crtl mice were 0.32 ± 0.03 cm3 and 0.57 ± 0.02 g in contrast to 0.3 ± 0.05 cm3 and 0.589 ± 0.03 g in Lenti-CTHRC1 mice (Fig. 4H and I).
CTHRC1 promotes cervical cancer cell migration and invasion in vitro and metastasis in vivo
We next investigated the effects of CTHRC1 on cervical cancer cell migration and invasion in vitro. The results showed that compared to the control group, silencing of CTHRC1 significantly inhibited Caski (Fig. 5A,C,D and F) and Ms751 (Fig. 5B,C,E and F) cell migration in vitro by wound healing assay and transwell migration assay. Moreover, silencing of CTHRC1 also suppressed cervical cancer cell invasion in vitro by transwell invasion assay (Fig. 5G–I). On the other hand, the overexpression of CTHRC1 significantly promoted Siha and Hela cell migration and invasion in vitro by wound healing assay, transwell migration assay and transwell invasion assay (Fig. 6A–E and Supplementary Figure 4A–D). Further, CTHRC1 was recombinantly expressed in 293 T cells, purified and verified by western blotting7 (Supplementary Figure 8A). Then, the purified recombinant CTHRC1 (rCTHRC1) protein was applied to primary Siha cells in a transwell migration assay. Compared to the control group, Siha cell migration was significantly enhanced by rCTHRC1 protein at doses of 10 nM and 100 nM. Moreover, the promotion of cell motility by the rCTHRC1 protein was dose-dependent (Fig. 6F and Supplementary Figure 4E).
To examine the role of CTHRC1 in cervical cancer cells metastasis in vivo, using a microsyringe, the pulmonary of nude mice were orthotopically inoculated with Lenti-CTHRC1/Siha or Lenti-Crtl/Siha cells. After four weeks, the mice were sacrificed and their pulmonarys were examined. Histological examination of the pulmonary tissue showed that CTHRC1 overexpression promoted the metastatic of cervical cancer in vivo (Fig. 6G). The number of pulmonary metastatic nodules was lower in the mice inoculated with the Lenti-Crtl/Siha cells than in the mice inoculated with the Lenti- CTHRC1/Siha cells (Fig. 6H).
E6/E7-p53- POU2F1 axis regulates CTHRC1 high expression in cervical cancer
Furthermore, we investigated the potential mechanisms of how E6/E7 regulates the expression CTHRC1. It is well-known that E6/E7 oncogenic proteins induces the transformation of epithelial cells, through the disruption of p53 function8. So we hypothesized E6/E7 may regulate the expression of CTHRC1 through p53 in cervical cancer. Therefore, we used several on-line tools, like JASPAR (http://jaspar.genereg.net/) and InsulatorDB: (http://insulatordb.utmem.edu) and analyzed whether the promoter region of CTHRC1 has some binding sites for p53. But we did not find any p53 binding sites located in the promoter region of CTHRC1, suggesting p53 may not directly regulate the expression of CTHRC1. Other transcription factors may act as an intermediator between p53 and CTHRC1.
To find which specific transcription factor directly regulates CTHRC1 expression by silencing of E6/E7, the transcription profiling microarray of Caski and Ms751 after silencing of E6/E7 was further analyzed. The results showed that 7 transcription factors (POU2F1, RORA, GMNN, NFE2L3, HES6, CSRNP1, PSIP1) were significantly downregulated (fold change >3, P < 0.05) (Fig. 7A). However, our qPCR results showed that only the mRNA expression of POU2F1 reduced when knockdown E6/E7 (Fig. 7B and Supplementary Figure 5A). Combining with the analysis of on-line tools, JASPAR and InsulatorDB:, transcription factor POU2F1 may be the direct regulator of CTHRC1 expression (Fig. 7C), which was confirmed by ChIP assay in Caski cells (Supplementary Figure 5B). The results showed that POU2F1 could bind to CTHRC1 promoter at three different regions (Fig. 7D,E and Supplementary Figure 7A). Furthermore, the expression of CTHRC1 was greatly reduced in Caski cells after silencing of POU2F1 (Fig. 7F and Supplementary Figure 5C). Together, these data indicated that transcription factor POU2F1 can directly regulate CTHRC1 expression in cervical cancer cells.
We further asked whether p53 can directly regulate the expression of POU2F1. Analyzed by JASPAR and InsulatorDB:, we found the promoter region of POU2F1 do have the binding sites for p53. ChIP assay further confirmed that p53 can directly bind to the promoter region of POU2F1 in cervical cancer cells (Fig. 8A,B, Supplementary Figures 5E and 7B). Moreover, the expression of POU2F1 was increased after silencing of p53 in Caski cells (Fig. 8C and Supplementary Figure 5D). Together, these data indicated that CTHRC1 expression was directly regulated by E6/E7-p53- POU2F1 axis in cervical cancer.
CTHRC1 activates Wnt/PCP signaling pathway
It has been reported that CTHRC1 selectively activated Wnt PCP signaling by stabilizing the Wnt-receptor complex9. Here, we examined whether CTHRC1 can affect the canonical Wnt pathway or the non-canonical Wnt pathway in cervical cancer cells. A Wnt/β-catenin reporter plasmid (TCF/catenin plasmid) and Wnt/PCP reporter plasmid (ATF2 plasmid) were transfected into cervical cancer cells, Siha and Hela. After transfection with the plasmids for 24 h, recombinant CTHRC1 or vehicle control was added and luciferase activity was determined. The results showed that Wnt/β-catenin signaling was inhibited while the non-canonical Wnt/PCP signaling was activated by rCTHRC1 protein in Siha and Hela cells. Moreover, the activation/inhibition of Wnt signaling by the rCTHRC1 protein was dose-dependent (Fig. 8D and E). Then we examined the effect of CTHRC1 on the JNK activation after knockdown the Wnt/PCP pathway-specific coreceptors ROR2 and VANGL2. The results showed that phosphorylation levels of JNK were increased when treated with rCTHRC1 at doses of 100 nM. Moreover, phosphorylation levels of JNK were decreased after knockdown of ROR2, VANGL2 or ROR2 + VANGL2, respectively, compared to that of the control group (Fig. 8G,H and Supplementary Figure 8B,C). ATF2 luciferase reporter assay showed the promoting effect of rCTHRC1 protein on Wnt/PCP signaling was almost blocked by sliencing of ROR2, VANGL2 or ROR2 + VANGL2, respectively (Fig. 8F).
CTHRC1 is highly expressed in the serum of cervical cancer patients
Secreted proteins are ideal candidates of diagnostic and prognostic markers, which can be easily detected in the serum of patients. As a secreted protein, we determined the diagnostic value of CTHRC1 for cervical cancer patients. We measured the serum levels of CTHRC1 in 72 healthy people, 74 CIN patients and 119 cervical cancer patients. The results showed the serum CTHRC1 levels of cervical cancer patients, CIN patients and healthy people are 12.1 ± 0.89 ng/ml, 8.157 ± 0.5100 ng/ml and 7.525 ± 0.4762 ng/ml, respectively. The concentrations of CTHRC1 in serum of cervical cancer were significantly higher than those in CIN patients and healthy people. The difference between healthy controls and CIN patients was not significant (Fig. 9A). As serum squamous carcinoma antigen (SCC-Ag) value is a clinical-used diagnostic marker for cervical cancer, we drew ROC curve of CTHRC1, SCC-Ag and combined CTHRC1 and SCC-Ag to assess the value of CTHRC1 as a serum marker for cervical cancer. For diagnosing cervical cancer, the overall classification accuracy of CTHRC1 was 69.4%, with 48.7% sensitivity and 86% specificity (Table 2). A multivariate function combining measurement of serum concentrations of SCC-Ag and CTHRC1 improved overall sensitivity for detection of cervical cancer to 88.2%. Combining measurement of these two markers can improve the AUC (area under roc curve) to 0.909 ± 0.022. (Fig. 9B).
Discussion
Although there has been an effective early screening tool for cervical cancer, cervical cancer is still one of the most common cancers among women of reproductive age in low- and middle-income countries10. Moreover, using traditional treatment, the 5 years survival rate of cervical cancer patients is relatively low, due to cancer invasion and metastasis10. Tumor microenvironment, especially extracellular matrix proteins, an important components of tumor microenvironment, play a crucial role in tumor invasion and metastasis. Interactions between extracellular matrix proteins and their receptors initiate downstream signaling pathways leading to tumor invasion and metastasis11. At present, the mechanism of extracellular matrix proteins in cervical cancer microenvironment remain largely elusive12. CTHRC1, an extracellular matrix protein, was identified in a screen for differentially expressed sequences in balloon-injured versus normal arteries13. CTHRC1 expression is elevated in many human solid tumors, such as melanoma14, non small cell lung cancer15, colorectal cancer16 and gastric carcinoma17, and is associated with cancer tissue invasion and metastasis. This study showed that
CTHRC1 is highly expressed in cervical cancer and promotes cervical cancer cell migration and invasion in vitro and metastasis in vivo. CTHRC1, an extracellular matrix protein, is secreted by cervical cancer cells and acts in a paracrine manner for regulating stromal cells in cancer microenvironment, eg. immune cells, fibroblast and endothelial cells, to influence the invasion and metastasis of cervical cancer.
HPV16 and HPV18 are two of the most important high-risk types of HPV associated with cervical cancer, and about 70% of cervical cancer cases are associated with HPV16 and HPV 1818. The E6 and E7 oncoproteins interfere with cell cycle regulators and induce genomic instability, which results in a malignant phenotype19. In addition to cervical cancer, E6/E7 is also associated with other tumors. It has been reported that HPV E6-induced promoter hypermethylation of the XRCC3 and XRCC5 DNA repair genes contributes to lung tumorigenesis in nonsmokers20. HPV-16 E6 promotes tumorigenesis in esophageal cancer via down-regulation of miR-125b21. However, little is known about how E6/E7 promote the development of cancer by remodeling the microenvironment. In this study, we silenced E6/E7 in Caski and Ms751 cell and the whole-genome microarray analysis showed that many tumor microenvironment associated genes were down-regulated, such as NCR3, a gene associated with immune response, and BIRC3, a gene related to regulation of inflammatory response. It suggests that E6/E7 may be closely related to many aspects of tumor microenvironment.
Many studies have demonstrated that the interaction between tumor cells and their microenvironment plays an important role in the process of tumorigenesis22. Tumor microenvironment is a complex integrated system, which is different from the microenvironment formed from normal cells with their surrounding tissues. Tumor associated fibroblasts have a profound influence on the development and progression of carcinomas23. The immune system has the capacity to promote carcinogenesis, tumor progression, and metastasis24. The crosstalk between malignant and nonmalignant cells via cytokines and chemokines plays a major role in the various steps of breast cancer progression25,26,27. Many studies have reported that the tumor microenvironment is the key factor for the invasion and metastasis of cervical cancer28,29,30. It is well-known that HPV E6/E7 is a key factor in the pathogenesis of cervical cancer. The major role of E6 is to mediate the degradation of p53 and bind to PDZ-domains on DLG (discs large) and hDLG (Drosophila large) tumor suppressor genes. The primary function of the E7 protein is to inactivate members of the pRb family of tumor suppressor proteins. However, its relationship with the tumor microenvironment is rarely reported. In this study, by silencing E6/E7 in HPV16 and HPV18 infected cervical cancer cells, we found that E6/E7 can regulate many microenvironment factors, like CTHRC1. Further detailed mechanism studies showed that CTHRC1 expression was finely regulated by E6/E7-p53- POU2F1 axis in cervical cancer.
Our study explored the relationship between E6/E7 and the extracellular matrix proteins in the tumor microenvironment, which extends a new theoretical basis for E6/E7 is the key to cervical cancer. However, there are still some limitations in our research. Many microenvironmental factors are significantly altered by silencing of E6/E7, but we only studied the function of CTHRC1 in cervical cancer. In addition, CTHRC1 may have other functions in tumor microenvironment, like microenvironment remodeling or immune response, etc.
In the future, based on this study, we will further explore the relationship between E6/E7 and other factors in the tumor microenvironment, especially uncovering the underlying molecular mechanisms that E6/E7 promotes cervical tumor progression by suppressing the immune response.
Methods and Materials
Clinical samples
Human cervical tissue microarray contained 101 cervical squamous cell carcinoma tissue samples, 29 cervical adenocarcinoma tissue samples, 19 cervical intraepithelial neoplasia (CIN) and 30 normal cervical tissues. These tissues were obtained from the Department of Gynecology, Changzhou Maternal and Child Care Hospital and the Department of Obstetrics and Gynecology, Fengxian Hospital, Southern Medical University. None of them had received chemotherapy, radiotherapy and other related anti-tumor therapies before surgery. The institutional ethics committee of the Southern Medical University approved the study protocol, and written informed consent was obtained from participants. The human experiments were performed in accordance with the relevant guidelines, including any relevant details.
Cell Proliferation Assay, Migration Assay, Invasion Assay, and In Vivo Tumor Formation Assay
The details for cell proliferation assay, migration assay and invasion assay are described in the Supporting Information. All animal experiments were approved by the Ethics Review Board of the Southern Medical University and conducted following institutional guidelines.
Whole-genome microarray construction and Transcriptional profiling microarray
A whole-genome microarray of silencing E6/E7-group and control group in Caski and Ms751 cell lines were done in Shanghai BoHao Biotechnology Co. Ltd (Hao Biotechnology Co, Shanghai, China). A transcriptional profiling microarray of silencing E6/E7 group and control group in Caski and Ms751 cell lines were done in Shanghai BoHao Biotechnology Co. Ltd (Hao Biotechnology Co, Shanghai, China). The details are described in the Supporting Information.
CTHRC1 Recombinant Protein Expression, Purification and Verification
CTHRC1 was recombinantly expressed in 293 T cells, and further purified and verified by western blotting. The details are described in the Supporting Information.
Transcriptional reporter gene assay
A Wnt/β-catenin reporter plasmid (TCF/catenin plasmid) and Wnt/PCP reporter plasmid (ATF2 plasmid) were transfected into cervical cancer cells, Siha and Hela. The details are described in the Supporting Information.
The details for immunohistochemistry, cell culture, real-time polymerase chain reaction (PCR), western blotting, lentivirus production and transduction, CTHRC1 recombinant protein expression, purification and verification, and luciferase reporter assays are described in the Supporting Information.
Statistical analyses
Statistical analyses were conducted using SPSS 21.0 software (Chicago, IL, USA). We performed chi-squared tests in cross tables to assess the relationships between expression levels of CTHRC1 and clinicopathological factors. All statistical tests were two-sided. One-way analysis of variance (ANOVA, Post-hoc testing) was used to compare groups. P value less than 0.05 was considered statistically significant.
Additional Information
How to cite this article: Zhang, R. et al. E6/E7-P53-POU2F1-CTHRC1 axis promotes cervical cancer metastasis and activates Wnt/PCP pathway. Sci. Rep. 7, 44744; doi: 10.1038/srep44744 (2017).
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
References
Clifford, G. M. et al. Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet 366, 991–998, doi: 10.1016/s0140-6736(05)67069-9 (2005).
Silvia de Sanjose, W. G. V. Q., Laia Alemany, Daan T Geraets, Jo Ellen, Klaustermeier. et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncology 11, 1048–1056, doi: 10.1016/s1470-2045(10)70230-8 (2010).
Ghittoni, R. et al. The biological properties of E6 and E7 oncoproteins from human papillomaviruses. Virus Genes 40, 1–13, doi: 10.1007/s11262-009-0412-8 (2010).
Gribben J, R. A., Gascoyne, R. & Lenz, G. Targeting the microenvironment. Leuk Lymphoma 51, Suppl 1, 34–40, doi: 10.3109/10428194.2010.500072. (2010).
Xu, Y., Xia, X. & Pan, H. Active autophagy in the tumor microenvironment: A novel mechanism for cancer metastasis. Oncol Lett 5, 411–416, doi: 10.3892/ol.2012.1015 (2013).
Wong, G. S. & Rustgi, A. K. Matricellular proteins: priming the tumour microenvironment for cancer development and metastasis. British journal of cancer 108, 755–761, doi: 10.1038/bjc.2012.592 (2013).
Nie, H. et al. Mineralocorticoid receptor suppresses cancer progression and the Warburg effect by modulating the miR-338-3p-PKLR axis in hepatocellular carcinoma. Hepatology 62, 1145–1159, doi: 10.1002/hep.27940 (2015).
Martin Scheffner, B. A. W., Jon M. Huibregtse, Arnold J. Levine, Peter & M. Howley . The E6 oncoprotein encoded by human papillomavirus type-16 and type-18 promotes the degradation of P53. Cell 63, 1129–1136 (1990).
Yamamoto, S. et al. Cthrc1 selectively activates the planar cell polarity pathway of Wnt signaling by stabilizing the Wnt-receptor complex. Dev Cell 15, 23–36, doi: 10.1016/j.devcel.2008.05.007 (2008).
Chidyaonga-Maseko, F., Chirwa, M. L. & Muula, A. S. Underutilization of cervical cancer prevention services in low and middle income countries: a review of contributing factors. Pan Afr Med J 21, 231, doi: 10.11604/pamj.2015.21.231.6350 (2015).
Multhaupt, H. A., Leitinger, B., Gullberg, D. & Couchman, J. R. Extracellular matrix component signaling in cancer. Advanced drug delivery reviews, doi: 10.1016/j.addr.2015.10.013 (2015).
Hui, L. & Chen, Y. Tumor microenvironment: Sanctuary of the devil. Cancer letters 368, 7–13, doi: 10.1016/j.canlet.2015.07.039 (2015).
Pyagay, P. et al. Collagen triple helix repeat containing 1, a novel secreted protein in injured and diseased arteries, inhibits collagen expression and promotes cell migration. Circ Res 96, 261–268, doi: 10.1161/01.RES.0000154262.07264.12 (2005).
Eriksson, J. et al. Gene expression analyses of primary melanomas reveal CTHRC1 as an important player in melanoma progression. Oncotarget, doi: 10.18632/oncotarget.7604 (2016).
Chen, S. et al. microRNA-30b inhibits cell invasion and migration through targeting collagen triple helix repeat containing 1 in non-small cell lung cancer. Cancer cell international 15, 85, doi: 10.1186/s12935-015-0236-7 (2015).
Yang, X. M. et al. CTHRC1 promotes human colorectal cancer cell proliferation and invasiveness by activating Wnt/PCP signaling. International journal of clinical and experimental pathology 8, 12793–12801 (2015).
Lee, C. E. et al. Collagen Triple Helix Repeat Containing-1 (CTHRC1) Expression in Oral Squamous Cell Carcinoma (OSCC): Prognostic Value and Clinico-Pathological Implications. International journal of medical sciences 12, 937–945, doi: 10.7150/ijms.11605 (2015).
Smith, J. S. et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. International journal of cancer . Journal international du cancer 121, 621–632, doi: 10.1002/ijc.22527 (2007).
Bello, J. O. et al. Regulation of the Wnt/beta-Catenin Signaling Pathway by Human Papillomavirus E6 and E7 Oncoproteins. Viruses 7, 4734–4755, doi: 10.3390/v7082842 (2015).
Cheng Y. W., L. F., Chen & C. Y., Hsu NY. Environmental exposure and HPV infection may act synergistically to induce lung tumorigenesis in nonsmokers. Oncotarget 23, doi: 10.18632/oncotarget (2016).
Zang B., H. G., Wang X., Zheng & S. HPV-16 E6 promotes cell growth of esophageal cancer via downregulation of miR-125b and activation of Wnt/β-catenin signaling pathway. Int J Clin Exp Pathol 8, 13687–13694 (2015).
Joyce, J. A. & Pollard, J. W. Microenvironmental regulation of metastasis. Nature reviews. Cancer 9, 239–252, doi: 10.1038/nrc2618 (2009).
Bhowmick, N. A., Neilson, E. G. & Moses, H. L. Stromal fibroblasts in cancer initiation and progression. Nature 432, 332–337, doi: 10.1038/nature03096 (2004).
Ostrand-Rosenberg, S. Immune surveillance: a balance between protumor and antitumor immunity. Curr Opin Genet Dev 18, 11–18, doi: 10.1016/j.gde.2007.12.007 (2008).
Beacham, D. A. & Cukierman, E. Stromagenesis: the changing face of fibroblastic microenvironments during tumor progression. Seminars in cancer biology 15, 329–341, doi: 10.1016/j.semcancer.2005.05.003 (2005).
Wels, J., Kaplan, R. N., Rafii, S. & Lyden, D. Migratory neighbors and distant invaders: tumor-associated niche cells. Genes Dev 22, 559–574, doi: 10.1101/gad.1636908 (2008).
Senst, C. et al. Prospective dual role of mesenchymal stem cells in breast tumor microenvironment. Breast Cancer Res Treat 137, 69–79, doi: 10.1007/s10549-012-2321-0 (2013).
Ellingsen, C., Walenta, S., Hompland, T., Mueller-Klieser, W. & Rofstad, E. K. The Microenvironment of Cervical Carcinoma Xenografts: Associations with Lymph Node Metastasis and Its Assessment by DCE-MRI. Transl Oncol 6, 607–617 (2013).
Stone, S. C., Rossetti, R. A., Lima, A. M. & Lepique, A. P. HPV associated tumor cells control tumor microenvironment and leukocytosis in experimental models. Immun Inflamm Dis 2, 63–75, doi: 10.1002/iid3.21 (2014).
DeCarlo, C. A. et al. Toll-like receptor transcriptome in the HPV-positive cervical cancer microenvironment. Clin Dev Immunol 2012, 785825, doi: 10.1155/2012/785825 (2012).
Acknowledgements
This work was supported by the National Natural Science Foundation of China [grant numbers 81472445 and 81672587 to R. Zhang, 81101600 to X-M. Yang], the Scientific and Technological Innovation Act Program of Shanghai Science and Technology Commission (grant number 14411973100 to R. Zhang) and the Scientific and Technological Innovation Act Program of Fengxian Science and Technology Commission (grant number 20160908 to H. Lu)
Author information
Authors and Affiliations
Contributions
R.Z., H.L. and Y.Y.L. contribute equally to the work. R.Z., H.L., Z.Y.W. and X.C.J. drafted the manuscript. X.M.Y. and L.Y.Z. designed and conducted the cell proliferation assay, migration assay, invasion assay. G.D.Y. and W.W.S. conducted the in vivo tumor formation assay. Y.Y.L., J.H.W., C.C.Z., F.G. and T.J.L. performed the rest of the experiments. P.C.J. and Y.R. provided clinical tissues. All authors read and approved the final manuscript.
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Supplementary information
Rights and permissions
This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
About this article
Cite this article
Zhang, R., Lu, H., Lyu, Yy. et al. E6/E7-P53-POU2F1-CTHRC1 axis promotes cervical cancer metastasis and activates Wnt/PCP pathway. Sci Rep 7, 44744 (2017). https://doi.org/10.1038/srep44744
Received:
Accepted:
Published:
DOI: https://doi.org/10.1038/srep44744
This article is cited by
-
Hsa-miR-194-5p and hsa-miR-195-5p are down-regulated expressed in high dysplasia HPV-positive Pap smear samples compared to normal cytology HPV-positive Pap smear samples
BMC Infectious Diseases (2024)
-
HPV E6/E7: insights into their regulatory role and mechanism in signaling pathways in HPV-associated tumor
Cancer Gene Therapy (2024)
-
CTHRC1 promotes colorectal cancer progression by recruiting tumor-associated macrophages via up-regulation of CCL15
Journal of Molecular Medicine (2024)
-
Multidimensional outlook on the pathophysiology of cervical cancer invasion and metastasis
Molecular and Cellular Biochemistry (2023)
-
Using biological information to analyze potential miRNA-mRNA regulatory networks in the plasma of patients with non-small cell lung cancer
BMC Cancer (2022)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.